BR0113644A - Usos do inibidor de pde5 no tratamento de enxaqueca - Google Patents
Usos do inibidor de pde5 no tratamento de enxaquecaInfo
- Publication number
- BR0113644A BR0113644A BR0113644-5A BR0113644A BR0113644A BR 0113644 A BR0113644 A BR 0113644A BR 0113644 A BR0113644 A BR 0113644A BR 0113644 A BR0113644 A BR 0113644A
- Authority
- BR
- Brazil
- Prior art keywords
- pde5 inhibitor
- migraine
- treatment
- pde5
- inhibitor
- Prior art date
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 4
- 208000019695 Migraine disease Diseases 0.000 title abstract 2
- 206010027599 migraine Diseases 0.000 title abstract 2
- 229940125684 antimigraine agent Drugs 0.000 abstract 1
- 239000002282 antimigraine agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"USOS DO INIBIDOR DE PDE5 NO TRATAMENTO DE ENXAQUECA". é revelado um método para tratamento de enxaqueca usando um inibidor de PDE5, isoladamente ou em combinação com um segundo inibidor de PDE5 e/ou outros agentes antienxaqueca.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22908300P | 2000-08-30 | 2000-08-30 | |
PCT/US2001/026740 WO2002019213A2 (en) | 2000-08-30 | 2001-08-27 | Method for treatment of migraine using pde5 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0113644A true BR0113644A (pt) | 2003-07-29 |
Family
ID=22859786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0113644-5A BR0113644A (pt) | 2000-08-30 | 2001-08-27 | Usos do inibidor de pde5 no tratamento de enxaqueca |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1313478A2 (pt) |
JP (1) | JP2004507514A (pt) |
CN (1) | CN1471397A (pt) |
AU (1) | AU2001286832A1 (pt) |
BR (1) | BR0113644A (pt) |
CA (1) | CA2419623A1 (pt) |
MX (1) | MXPA03001717A (pt) |
WO (1) | WO2002019213A2 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
DE10325813B4 (de) | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
WO2008097664A1 (en) | 2007-02-11 | 2008-08-14 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
US20080260643A1 (en) | 2007-03-27 | 2008-10-23 | Omeros Corporation | Use of pde7 inhibitors for the treatment of movement disorders |
EP2273880B1 (en) | 2008-04-28 | 2014-12-31 | Zogenix, Inc. | Novel formulations for treatment of migraine |
US10010514B2 (en) | 2010-07-08 | 2018-07-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US20130323288A1 (en) | 2010-07-08 | 2013-12-05 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
US9415048B2 (en) | 2010-07-08 | 2016-08-16 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US9532959B2 (en) | 2010-07-08 | 2017-01-03 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for reducing frequency of urination and method of use thereof |
US20130040971A1 (en) * | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
US10278925B2 (en) | 2012-01-04 | 2019-05-07 | Wellesley Pharmaceuticals, Llc | Delayed-release formulations, methods of making and use thereof |
KR20180023057A (ko) | 2012-01-04 | 2018-03-06 | 웰즐리 파마슈티컬스 엘엘씨 | 배뇨 빈도를 감소시키기 위한 서방형 제제 및 이의 사용 방법 |
US10105330B2 (en) | 2012-01-04 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Extended, delayed and immediate release formulation method of manufacturing and use thereof |
CN107661326A (zh) * | 2012-07-27 | 2018-02-06 | 韦尔斯利医药有限公司 | 用于遗尿的药物制剂及其使用方法 |
CA2895816C (en) | 2012-12-21 | 2021-02-23 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
US10792326B2 (en) | 2013-06-28 | 2020-10-06 | Wellesley Pharmaceuticals, Llc | Pharmaceutical formulation for bedwetting and method of use thereof |
JP2017114764A (ja) * | 2014-04-25 | 2017-06-29 | 武田薬品工業株式会社 | 片頭痛治療剤 |
US10105328B2 (en) | 2014-06-06 | 2018-10-23 | Wellesley Pharmaceuticals, Llc | Composition for reducing frequency of urination, method of making and use thereof |
-
2001
- 2001-08-27 WO PCT/US2001/026740 patent/WO2002019213A2/en not_active Application Discontinuation
- 2001-08-27 CA CA002419623A patent/CA2419623A1/en not_active Abandoned
- 2001-08-27 EP EP01966306A patent/EP1313478A2/en not_active Withdrawn
- 2001-08-27 JP JP2002523251A patent/JP2004507514A/ja not_active Withdrawn
- 2001-08-27 AU AU2001286832A patent/AU2001286832A1/en not_active Abandoned
- 2001-08-27 BR BR0113644-5A patent/BR0113644A/pt not_active Application Discontinuation
- 2001-08-27 MX MXPA03001717A patent/MXPA03001717A/es unknown
- 2001-08-27 CN CNA018177832A patent/CN1471397A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2002019213A3 (en) | 2002-10-17 |
MXPA03001717A (es) | 2003-09-22 |
CA2419623A1 (en) | 2002-03-07 |
AU2001286832A1 (en) | 2002-03-13 |
CN1471397A (zh) | 2004-01-28 |
WO2002019213A2 (en) | 2002-03-07 |
EP1313478A2 (en) | 2003-05-28 |
JP2004507514A (ja) | 2004-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113644A (pt) | Usos do inibidor de pde5 no tratamento de enxaqueca | |
DK0755249T3 (da) | Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom | |
WO2000038665A3 (en) | Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia | |
SE9404196D0 (sv) | New antithrombotic formulation | |
FR2759581B1 (fr) | Dispositif de traitement, notamment par moxa, de type acupressure | |
CA2282654A1 (en) | Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder | |
PT1143967E (pt) | Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas | |
BR9806118A (pt) | Processos para tratamento de pigmentação de pele | |
ID21863A (id) | Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak | |
PT1052905E (pt) | Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol | |
BR0214481A (pt) | Método e composição para potenciação de um analgésico opiáceo | |
BR0306820A (pt) | Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus | |
DK1250292T3 (da) | Fremgangsmåde til at forhindre opfirmering af mikroorganismer i et ækvatisk system | |
TR200402670T4 (tr) | Obezitenin tedavisi ve/veya profilaksına uygun bileşiklerin bulunması için yöntem | |
ES2178405T3 (es) | Uso de selegilina o de desmetilselegilina para tratar heridas, quemaduras y lesiones cutaneas. | |
ID24184A (id) | Obat untuk perawatan disfungsi ereksi | |
BR9811003A (pt) | processo para a prevenção ou tratamento de prurido em um paciente mamìfero | |
BRPI0415187A (pt) | composição, método para matar bactérias, e, usos de composição e de bacteriófago | |
WO2001052711A3 (de) | Reinigungskörper aus edelstahl | |
BR0112721A (pt) | Uso de fosfato de estramustina no tratamento de metastase óssea | |
ATE291425T1 (de) | R-eliprodil zur behandlung von glaucoma | |
LV11593A (lv) | Dimetikona pielietojums aizcietejumu arstesana | |
ATE236633T1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
BR0002640A (pt) | Uso de simeticona para tratar colite ulcerativa | |
ATE491457T1 (de) | Kombinationstherapie gegen tumoren mit substituierten acryloyl-distamycin-derivaten, taxanen und/oder antimetaboliten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 45/06 (2006.01), A61K 31/496 (2006.01), A61K |